Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Virus-like particles |
Clinical data | |
Other names | VBI-2902a |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2][3][4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5]
((cite journal))
: Cite journal requires |journal=
(help)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|